SOGUG-PRINCIS is a retrospective (regarding patient inclusion) and prospective follow-up, epidemiological, non-interventional, non-blinded, non-randomized, multicenter, national observational study with drugs. This study will collect data from patients with genitourinary tumors to analyze the effectiveness under routine clinical practice conditions of drugs recently approved for funding in the Spanish National Health System.
In all cases, the decision to start treatment will be made prior to and independently of participation in the study, which will be limited to subsequently collecting the data necessary to assess the objectives of the study.
This study will serve as a registry for genitourinary cancers. Every time a new drug will be authorized, a new subproject with a primary endpoint will be opened to recruitment. The substudy will try to validate with real-world data the endpoints reported in the phase III clinical trials that led to the marketin authorization.
Patients ≥18 years old.
Patients granting the ICF unless exemption or exceptions mentioned below.
Histological diagnosis of malignant neoplasia originating in the genitourinary system: kidney, renal pelvis, ureter, bladder, prostate, testicle and germinal tissue of other locations, urethra, penis, or seminal vesicles.
Patients have started treatment with medications whose positive resolution of financing by the Spanish National Health System for the aforementioned tumors has been after January 1, 2023.
Patients previously treated at another centre who have subsequently been referred to one of the participating centres. In this case, the patient will be included in the centre where treatment was started, or in the second centre if the first is not part of this study.
Patients who do not meet any of the inclusion criteria.
Evidence of an express objection by the subject or his/her legal representative to participate in the study.
Patients with genitourinary cancers treated with new therapies following the standard clinical practice
Cohort
Other
darolutamide
DrugDarolutamide in combination with androgen deprivation therapy and docetaxel. Following the posology and administration details of its marketing authorization and standard clinical practice
Nivolumab monotherapy
DrugAdjuvant nivolumab following after surgical removal of urothelial carcinoma. Following the posology and administration details of its marketing authorization and standard clinical practice
enfortumab vedotin
DrugFollowing the posology and administration details of its marketing authorization and standard clinical practice
Progresion-free survival rate at 18 months
For TRIDA substudy. Defined as the percentage of patients alive and free of progression of the disease (estimated by Kaplan-Meier method) at 18 months. Patients without event are censored in their last follow-up
Relapse-free survival rate at 24 months
For NIADY substudy. Defined as the percentage of patients alive and with no disease recurrence (estimated by Kaplan-Meier method) at 24 months
Overall survival rate at 12 months
For EV3aL substudy Defined as the percentage of patients alive (estimated by Kaplan-Meier method) at 12 months
Click on the lead sponsor to view all of their trials.
Spanish Oncology Genito-Urinary Group
Lead sponsor
MFAR
Collaborator
